American Society of Hirudotherapy

Destabilase-2

Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Destabilase-2 compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaDestabilase-212.5 kDa
Molecular weight (kilodaltons) of Destabilase-2 (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Destabilase-2 is documented mechanistically only; no human evidence. Reported fibrin-cleaving activity does NOT establish clinical thrombolytic efficacy, and no FDA-approved derivative exists.

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
12,500 Da
Source species
Hirudo medicinalis
Discovered
2005
Destabilase-2 molecular structure

Biological Targets

  • isopeptide ε-(γ-Glu)-Lys bonds in cross-linked fibrin

Key Citations

  1. Liu Z et al. (2019), Parasit Vectors

External Resources

    Related Fibrinolytic Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.